These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 22346751

  • 1. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR, Kwek SS, Kenney SC.
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
    Kraus RJ, Yu X, Cordes BA, Sathiamoorthi S, Iempridee T, Nawandar DM, Ma S, Romero-Masters JC, McChesney KG, Lin Z, Makielski KR, Lee DL, Lambert PF, Johannsen EC, Kenney SC, Mertz JE.
    PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
    [Abstract] [Full Text] [Related]

  • 5. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
    Reusch JA, Nawandar DM, Wright KL, Kenney SC, Mertz JE.
    J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
    [Abstract] [Full Text] [Related]

  • 6. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
    Woellmer A, Arteaga-Salas JM, Hammerschmidt W.
    PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
    Lupey-Green LN, Moquin SA, Martin KA, McDevitt SM, Hulse M, Caruso LB, Pomerantz RT, Miranda JL, Tempera I.
    Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
    [Abstract] [Full Text] [Related]

  • 9. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
    Siddiqi UZ, Vaidya AS, Li X, Marcon E, Tsao SW, Greenblatt J, Frappier L.
    J Virol; 2019 Oct 15; 93(20):. PubMed ID: 31341047
    [Abstract] [Full Text] [Related]

  • 10. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
    Romero-Masters JC, Huebner SM, Ohashi M, Bristol JA, Benner BE, Barlow EA, Turk GL, Nelson SE, Baiu DC, Van Sciver N, Ranheim EA, Gumperz J, Sherer NM, Farrell PJ, Johannsen EC, Kenney SC.
    PLoS Pathog; 2020 Feb 15; 16(2):e1008365. PubMed ID: 32059024
    [Abstract] [Full Text] [Related]

  • 11. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
    Kraus RJ, Cordes BA, Sathiamoorthi S, Patel P, Yuan X, Iempridee T, Yu X, Lee DL, Lambert PF, Mertz JE.
    J Virol; 2020 Aug 31; 94(18):. PubMed ID: 32641480
    [Abstract] [Full Text] [Related]

  • 12. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
    Gao Y, Wang L, Lei Z, Li J, Forrest JC, Liang X.
    J Gen Virol; 2019 May 31; 100(5):851-862. PubMed ID: 30907723
    [Abstract] [Full Text] [Related]

  • 13. The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites.
    Kalla M, Göbel C, Hammerschmidt W.
    J Virol; 2012 Jan 31; 86(1):447-58. PubMed ID: 22031942
    [Abstract] [Full Text] [Related]

  • 14. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
    Yu X, McCarthy PJ, Wang Z, Gorlen DA, Mertz JE.
    J Virol; 2012 Aug 31; 86(15):8086-96. PubMed ID: 22623769
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
    Wen W, Iwakiri D, Yamamoto K, Maruo S, Kanda T, Takada K.
    J Virol; 2007 Jan 31; 81(2):1037-42. PubMed ID: 17079287
    [Abstract] [Full Text] [Related]

  • 16. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
    Dunn LEM, Lu F, Su C, Lieberman PM, Baines JD.
    J Virol; 2023 Feb 28; 97(2):e0189422. PubMed ID: 36744959
    [Abstract] [Full Text] [Related]

  • 17. BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV.
    Schaeffner M, Mrozek-Gorska P, Buschle A, Woellmer A, Tagawa T, Cernilogar FM, Schotta G, Krietenstein N, Lieleg C, Korber P, Hammerschmidt W.
    Life Sci Alliance; 2019 Apr 28; 2(2):. PubMed ID: 30926617
    [Abstract] [Full Text] [Related]

  • 18. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
    Van Sciver N, Ohashi M, Pauly NP, Bristol JA, Nelson SE, Johannsen EC, Kenney SC.
    PLoS Pathog; 2021 Aug 28; 17(8):e1009783. PubMed ID: 34339458
    [Abstract] [Full Text] [Related]

  • 19. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
    Kim JY, Min YJ, Lee M-H, An YR, Ashktorab H, Smoot DT, Kwon SW, Lee SK.
    J Virol; 2024 Feb 20; 98(2):e0177623. PubMed ID: 38197630
    [Abstract] [Full Text] [Related]

  • 20. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
    Jung YJ, Choi H, Kim H, Lee SK.
    J Virol; 2014 Aug 20; 88(16):9027-37. PubMed ID: 24899173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.